Imatinib 800 mg daily induces deeper molecular responses than imatinib 400 mg daily: Results of SWOG S0325, an intergroup randomized PHASE II trial in newly diagnosed chronic phase chronic myeloid leukaemia

Michael W. Deininger, Kenneth J. Kopecky, Jerald P. Radich, Suzanne Kamel-Reid, Wendy Stock, Elisabeth M. Paietta, Peter D. Emanuel, Martin Tallman, Martha Wadleigh, Richard A. Larson, Jeffrey H. Lipton, Marilyn L. Slovak, Frederick R. Appelbaum, Brian J. Druker

Research output: Contribution to journalArticle

41 Citations (Scopus)

Abstract

Summary: The standard dose of imatinib for newly diagnosed patients with chronic phase chronic myeloid leukaemia (CP-CML) is 400 mg daily (IM400), but the optimal dose is unknown. This randomized phase II study compared the rates of molecular, haematological and cytogenetic response to IM400 vs. imatinib 400 mg twice daily (IM800) in 153 adult patients with CP-CML. Dose adjustments for toxicity were flexible to maximize retention on study. Molecular response (MR) at 12 months was deeper in the IM800 arm (4-log reduction of BCR-ABL1 mRNA: 25% vs. 10% of patients, P = 0·038; 3-log reduction: 53% vs. 35%, P = 0·049). During the first 12 months BCR-ABL1 levels in the IM800 arm were an average 2·9-fold lower than in the IM400 arm (P = 0·010). Complete haematological response was similar, but complete cytogenetic response was higher with IM800 (85% vs. 67%, P = 0·040). Grade 3-4 toxicities were more common for IM800 (58% vs. 31%, P = 0·0007), and were most commonly haematological. Few patients have relapsed, progressed or died, but both progression-free (P = 0·048) and relapse-free (P = 0·031) survival were superior for IM800. In newly diagnosed CP-CML patients, IM800 induced deeper MRs than IM400, with a trend for improved progression-free and overall survival, but was associated with more severe toxicity.

Original languageEnglish (US)
Pages (from-to)223-232
Number of pages10
JournalBritish Journal of Haematology
Volume164
Issue number2
DOIs
StatePublished - Jan 2014

Fingerprint

Leukemia, Myeloid, Chronic Phase
Cytogenetics
Disease-Free Survival
Imatinib Mesylate
Recurrence
Messenger RNA
Survival

Keywords

  • BCR-ABL1
  • Chronic myeloid leukaemia
  • Imatinib

ASJC Scopus subject areas

  • Hematology

Cite this

Imatinib 800 mg daily induces deeper molecular responses than imatinib 400 mg daily : Results of SWOG S0325, an intergroup randomized PHASE II trial in newly diagnosed chronic phase chronic myeloid leukaemia. / Deininger, Michael W.; Kopecky, Kenneth J.; Radich, Jerald P.; Kamel-Reid, Suzanne; Stock, Wendy; Paietta, Elisabeth M.; Emanuel, Peter D.; Tallman, Martin; Wadleigh, Martha; Larson, Richard A.; Lipton, Jeffrey H.; Slovak, Marilyn L.; Appelbaum, Frederick R.; Druker, Brian J.

In: British Journal of Haematology, Vol. 164, No. 2, 01.2014, p. 223-232.

Research output: Contribution to journalArticle

Deininger, MW, Kopecky, KJ, Radich, JP, Kamel-Reid, S, Stock, W, Paietta, EM, Emanuel, PD, Tallman, M, Wadleigh, M, Larson, RA, Lipton, JH, Slovak, ML, Appelbaum, FR & Druker, BJ 2014, 'Imatinib 800 mg daily induces deeper molecular responses than imatinib 400 mg daily: Results of SWOG S0325, an intergroup randomized PHASE II trial in newly diagnosed chronic phase chronic myeloid leukaemia', British Journal of Haematology, vol. 164, no. 2, pp. 223-232. https://doi.org/10.1111/bjh.12618
Deininger, Michael W. ; Kopecky, Kenneth J. ; Radich, Jerald P. ; Kamel-Reid, Suzanne ; Stock, Wendy ; Paietta, Elisabeth M. ; Emanuel, Peter D. ; Tallman, Martin ; Wadleigh, Martha ; Larson, Richard A. ; Lipton, Jeffrey H. ; Slovak, Marilyn L. ; Appelbaum, Frederick R. ; Druker, Brian J. / Imatinib 800 mg daily induces deeper molecular responses than imatinib 400 mg daily : Results of SWOG S0325, an intergroup randomized PHASE II trial in newly diagnosed chronic phase chronic myeloid leukaemia. In: British Journal of Haematology. 2014 ; Vol. 164, No. 2. pp. 223-232.
@article{81470fbf394c4f1a988481e8b46bfd1b,
title = "Imatinib 800 mg daily induces deeper molecular responses than imatinib 400 mg daily: Results of SWOG S0325, an intergroup randomized PHASE II trial in newly diagnosed chronic phase chronic myeloid leukaemia",
abstract = "Summary: The standard dose of imatinib for newly diagnosed patients with chronic phase chronic myeloid leukaemia (CP-CML) is 400 mg daily (IM400), but the optimal dose is unknown. This randomized phase II study compared the rates of molecular, haematological and cytogenetic response to IM400 vs. imatinib 400 mg twice daily (IM800) in 153 adult patients with CP-CML. Dose adjustments for toxicity were flexible to maximize retention on study. Molecular response (MR) at 12 months was deeper in the IM800 arm (4-log reduction of BCR-ABL1 mRNA: 25{\%} vs. 10{\%} of patients, P = 0·038; 3-log reduction: 53{\%} vs. 35{\%}, P = 0·049). During the first 12 months BCR-ABL1 levels in the IM800 arm were an average 2·9-fold lower than in the IM400 arm (P = 0·010). Complete haematological response was similar, but complete cytogenetic response was higher with IM800 (85{\%} vs. 67{\%}, P = 0·040). Grade 3-4 toxicities were more common for IM800 (58{\%} vs. 31{\%}, P = 0·0007), and were most commonly haematological. Few patients have relapsed, progressed or died, but both progression-free (P = 0·048) and relapse-free (P = 0·031) survival were superior for IM800. In newly diagnosed CP-CML patients, IM800 induced deeper MRs than IM400, with a trend for improved progression-free and overall survival, but was associated with more severe toxicity.",
keywords = "BCR-ABL1, Chronic myeloid leukaemia, Imatinib",
author = "Deininger, {Michael W.} and Kopecky, {Kenneth J.} and Radich, {Jerald P.} and Suzanne Kamel-Reid and Wendy Stock and Paietta, {Elisabeth M.} and Emanuel, {Peter D.} and Martin Tallman and Martha Wadleigh and Larson, {Richard A.} and Lipton, {Jeffrey H.} and Slovak, {Marilyn L.} and Appelbaum, {Frederick R.} and Druker, {Brian J.}",
year = "2014",
month = "1",
doi = "10.1111/bjh.12618",
language = "English (US)",
volume = "164",
pages = "223--232",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - Imatinib 800 mg daily induces deeper molecular responses than imatinib 400 mg daily

T2 - Results of SWOG S0325, an intergroup randomized PHASE II trial in newly diagnosed chronic phase chronic myeloid leukaemia

AU - Deininger, Michael W.

AU - Kopecky, Kenneth J.

AU - Radich, Jerald P.

AU - Kamel-Reid, Suzanne

AU - Stock, Wendy

AU - Paietta, Elisabeth M.

AU - Emanuel, Peter D.

AU - Tallman, Martin

AU - Wadleigh, Martha

AU - Larson, Richard A.

AU - Lipton, Jeffrey H.

AU - Slovak, Marilyn L.

AU - Appelbaum, Frederick R.

AU - Druker, Brian J.

PY - 2014/1

Y1 - 2014/1

N2 - Summary: The standard dose of imatinib for newly diagnosed patients with chronic phase chronic myeloid leukaemia (CP-CML) is 400 mg daily (IM400), but the optimal dose is unknown. This randomized phase II study compared the rates of molecular, haematological and cytogenetic response to IM400 vs. imatinib 400 mg twice daily (IM800) in 153 adult patients with CP-CML. Dose adjustments for toxicity were flexible to maximize retention on study. Molecular response (MR) at 12 months was deeper in the IM800 arm (4-log reduction of BCR-ABL1 mRNA: 25% vs. 10% of patients, P = 0·038; 3-log reduction: 53% vs. 35%, P = 0·049). During the first 12 months BCR-ABL1 levels in the IM800 arm were an average 2·9-fold lower than in the IM400 arm (P = 0·010). Complete haematological response was similar, but complete cytogenetic response was higher with IM800 (85% vs. 67%, P = 0·040). Grade 3-4 toxicities were more common for IM800 (58% vs. 31%, P = 0·0007), and were most commonly haematological. Few patients have relapsed, progressed or died, but both progression-free (P = 0·048) and relapse-free (P = 0·031) survival were superior for IM800. In newly diagnosed CP-CML patients, IM800 induced deeper MRs than IM400, with a trend for improved progression-free and overall survival, but was associated with more severe toxicity.

AB - Summary: The standard dose of imatinib for newly diagnosed patients with chronic phase chronic myeloid leukaemia (CP-CML) is 400 mg daily (IM400), but the optimal dose is unknown. This randomized phase II study compared the rates of molecular, haematological and cytogenetic response to IM400 vs. imatinib 400 mg twice daily (IM800) in 153 adult patients with CP-CML. Dose adjustments for toxicity were flexible to maximize retention on study. Molecular response (MR) at 12 months was deeper in the IM800 arm (4-log reduction of BCR-ABL1 mRNA: 25% vs. 10% of patients, P = 0·038; 3-log reduction: 53% vs. 35%, P = 0·049). During the first 12 months BCR-ABL1 levels in the IM800 arm were an average 2·9-fold lower than in the IM400 arm (P = 0·010). Complete haematological response was similar, but complete cytogenetic response was higher with IM800 (85% vs. 67%, P = 0·040). Grade 3-4 toxicities were more common for IM800 (58% vs. 31%, P = 0·0007), and were most commonly haematological. Few patients have relapsed, progressed or died, but both progression-free (P = 0·048) and relapse-free (P = 0·031) survival were superior for IM800. In newly diagnosed CP-CML patients, IM800 induced deeper MRs than IM400, with a trend for improved progression-free and overall survival, but was associated with more severe toxicity.

KW - BCR-ABL1

KW - Chronic myeloid leukaemia

KW - Imatinib

UR - http://www.scopus.com/inward/record.url?scp=84891628299&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84891628299&partnerID=8YFLogxK

U2 - 10.1111/bjh.12618

DO - 10.1111/bjh.12618

M3 - Article

C2 - 24383843

AN - SCOPUS:84891628299

VL - 164

SP - 223

EP - 232

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

IS - 2

ER -